Journal
JACC-BASIC TO TRANSLATIONAL SCIENCE
Volume 4, Issue 1, Pages 27-37Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacbts.2018.11.010
Keywords
diastole; heart failure with preserved ejection fraction; sodium-glucose-linked co-transporter-2 inhibitor; systole
Categories
Funding
- St. Michael's Hospital Foundation
- Boehringer Ingelheim
- Canada Research Chair program
- CIHR
- Ministry of Ontario
- Diabetes Investigator Award from Diabetes Canada
Ask authors/readers for more resources
Recent studies send an unambiguous signal that the class of agents known as sodium-glucose-linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear. Herein the authors utilize a rodent model of heart failure with preserved ejection fraction (HFpEF), and demonstrate that treatment with the SGLT2i empagliflozin, reduces left ventricular mass, improving both wall stress and diastolic function. These findings extend the observation that the main mechanism of action of empagliflozin involves improved hemodynamics (i.e., reduction in preload and afterload) and provide a rationale for upcoming trials in patients with HFpEF irrespective of glycemic status. (C) 2019 The Authors. Published by Elsevieron behalf of the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available